CULVER CITY, Calif.–(BUSINESS WIRE)–ImmunityBio, Inc. (NASDAQ: IBRX) today announced it has begun trading as a large cap company with approximately 398 million fully diluted shares outstanding following its merger with NantKwest. The combined company begins trading today on the Global Select Market of the Nasdaq exchange under the IBRX ticker. ImmunityBio is a leading late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating
News Ticker
- [ September 26, 2023 ] Muscle Lab Ignites a Wellness Evolution with the Launch of GPT-4 Driven Custom Recovery Plans and Smart Lab Los Angeles Biotech News
- [ September 26, 2023 ] Herbalife Steps Up to Support Healthy Active Lifestyles for 10th Consecutive Year as Nutrition Partner for Downtown Los Angeles YMCA’s Stair Climb & Urban Hike Los Angeles Biotech News
- [ September 26, 2023 ] CLININICAL LAB SCIENTIST I – PD – IRVINE HEMATOLOGY – Hoag Memorial Hospital Presbyterian – Irvine, CA Los Angeles Biotech Jobs
- [ September 26, 2023 ] How TikTok’s algorithm and audiences are finally convincing Big Pharma to join Los Angeles Biotech News
- [ September 26, 2023 ] Bristol Myers joins AstraZeneca in agreeing to drug price negotiation terms ahead of first deadline Los Angeles Biotech News
Copyright © 2023 Biotech Networks, LLC
